Clinical Evaluation of injectable Mitomycin-C in Trabeculectomy for Glaucoma Patients
DOI:
https://doi.org/10.51985/Keywords:
Efficacy, Glaucoma, Intraocular Pressure (IOP), Mitomycin C and TrabeculectomyAbstract
Objective: To evaluate the efficacy of injectable Mitomycin-C (MMC) administered at the bleb site during trabeculectomy in patients with glaucoma.
Study Design and Setting: This cross-sectional study was conducted at the Department of Ophthalmology, Unit-1, Dow Medical College, Dr. Ruth K. M. Pfau Civil Hospital Karachi, and SMBB Trauma Centre from January to June 2022.
Methodology: Data were obtained through non-probability consecutive sampling. After obtaining informed consent, patients meeting the diagnostic criteria and undergoing trabeculectomy were enrolled. Demographic data, including age, gender, and eye laterality, were recorded. Efficacy was defined as a postoperative intraocular pressure (IOP) reduction of more than 30% compared to preoperative values. Ophthalmic examinations included visual acuity, refraction, slit-lamp biomicroscopy, gonioscopy, and IOP measurement. The effect of MMC across different subgroups was analyzed using an independent t-test, with a p-value =0.05 considered statistically significant.
Results: A total of 62 patients underwent trabeculectomy with injectable MMC. The mean preoperative IOP was 32.81 ± 13.13 mmHg, while the mean postoperative IOP at one month was 13.88 ± 5.90 mmHg, indicating a significant reduction (p = 0.01). Over 30% IOP reduction was achieved in the majority of cases. Only five patients developed postoperative complications, including fibrosis and flat blebs.
Conclusion: Injectable Mitomycin-C is an effective adjunctive therapy in trabeculectomy, significantly lowering intraocular pressure and enhancing surgical success while minimizing postoperative scarring and surgical failure.
References
1. Nawab A, Sheikh J, Alam S, Kamali B. Tackling the Silent
Thief of Sight: Assessing Glaucoma Awareness, Knowledge,
and Risk of Prevalence in Karachi. Pakistan Journal of Public
Health. 2024 Mar 29;14(1):47-50. https://doi.org/10.32413
/pjph.v14i1.680
2. Abdelkareem HA. Relationship between Glaucoma Severity,
Vision-related Quality of Life and Perceived Wellbeing among
Older Adults. Damanhour Scientific Nursing Journal. 2024
Dec 1;2(4):114-33. http://dx.doi.org/10.21608/dsnj.
2025.334093.1043
3. Theventhiran AB, Kim G, Yao W. Fornix-based versus limbalbased conjunctival trabeculectomy flaps for glaucoma.
Cochrane Database of Systematic Reviews. 2021(8).
https://doi.org/10.1002/14651858.CD009380.pub2
4. Dave B, Patel M, Suresh S, Ginjupalli M, Surya A, Albdour
M, Kooner KS. Wound Modulations in Glaucoma Surgery:
A Systematic Review. Bioengineering. 2024 Apr 30;11(5):446.
https://doi.org/10.3390/bioengineering11050446
5. Shao CG, Sinha NR, Mohan RR, Webel AD. Novel therapies
for the prevention of fibrosis in glaucoma filtration surgery.
Biomedicines. 2023 Feb 21;11(3):657. https://doi.org/10.3390/
biomedicines11030657
6. Baindara P, Mandal SM. Bacteria and bacterial anticancer
agents as a promising alternative for cancer therapeutics.
Biochimie. 2020 Oct 1;177:164-89. https://doi.org/10.1016/
j.biochi.2020.07.020
7. Sacchi M, Tomaselli D, Ruggeri ML, Aiello FB, Sabella P,
Dore S, Pinna A, Mastropasqua R, Nubile M, Agnifili L.
Fighting Bleb Fibrosis After Glaucoma Surgery: Updated
Focus on Key Players and Novel Targets for Therapy.
International Journal of Molecular Sciences. 2025 Mar
5;26(5):2327. https://doi.org/10.3390/ijms26052327
8. Azhany Y, Siti-Fairuz MY, Ahmad A, Yusuf WN, Hou LJ,
Liza-Sharmini AT, Hamzah JC. Modulation Agents of Wound
Healing in Ocular Surgeries. Malaysian Journal of Medicine
and Health Sciences. 2024 Jan 1;20(1):293-303.
https://doi.org/10.47836/mjmhs.20.1.37
9. Mamidipaka A, Shi A, Addis V, He J, Lee R, Di Rosa I,
Salowe R, Ying GS, O’Brien J. Outcomes of Trabeculectomy
and Predictors of Success in Patients of African Ancestry
With Primary Open Angle Glaucoma. Journal of Glaucoma.
2025 Feb 1;34(2):127-35. http://dx.doi.org/10.1097/
IJG.0000000000002503
10. Kavitha S, Tejaswini SU, Venkatesh R, Zebardast N. Wound
modulation in glaucoma surgery: The role of anti-scarring
agents. Indian Journal of Ophthalmology. 2024 Mar
1;72(3):320-7. http://dx.doi.org/10.4103/IJO.IJO_2013_23
11. Maheshwari D, Pillai MR, Hm P, Kader MA, Rengappa R,
Pawar N. Long-term safety and efficacy of injection mitomycin
C (MMC) versus sponge application in trabeculectomies.
European Journal of Ophthalmology. 2024 Aug
2:11206721241266981. https://doi.org/10.1177/ 11206721
241266
12. Zheng J, Zhang A. Efficacy and safety of intraoperative
injection of mitomycin C during trabeculectomy: a systematic
review and meta-analysis. International Ophthalmology. 2024
Sep 6;44(1):372. https://link.springer.com/article/1
0.1007/s10792-024-03291-7
13. Qin ZX, Ying X, Han Q, et al. Outcomes and risk factors for
failure of trabeculectomy in glaucomatous patients in
Southwest China: a 325 eyes analysis. Int J Ophthalmol.
2023;16(3):367–374. https://pmc.ncbi.nlm.nih. gov/articles/
PMC10009591/
14. Do JL, Xu BY, Wong B, Camp A, Ngai P, Long C, Proudfoot
J, Moghimi S, Yan D, Welsbie DS, Weinreb RN. A randomized
controlled trial comparing subconjunctival injection to direct
scleral application of mitomycin C in trabeculectomy. American
journal of ophthalmology. 2020 Dec 1;220:45-52.
https://doi.org/ 10.1016/j.ajo.2020.07.002
15. Quist MS, Brown N, Bicket AK, Herndon LW. The Shortterm Effect of Subtenon Sponge Application Versus Subtenon
Irrigation of mitomycin-C on the outcomes of trabeculectomy
with express glaucoma filtration device: a randomized trial
.J. Glaucoma. 2018 Feb;27(2):148-56. http://dx.doi.org/10.1097
/IJG.0000000000000830
16. Wilkins M, Indar A, Wormald R. Intra-operative mitomycin
C for glaucoma surgery [review] Cochrane Database Syst
Rev. 2005;4:CD002897. https://pubmed.ncbi.nlm
.nih.gov/16235305/
17. Iester M, Ravinet E, Mermoud A. Postoperative
subconjunctival mitomycin-C injection after non-penetrating
glaucoma surgery. Journal of ocular pharmacology and
therapeutics. 2002 Aug 1;18(4):307-12. https://doi.org/10.1089/
1080768026021847
18. Annen DJ, Stürmer J. Follow-up of a pilot study of
trabeculectomy with low dosage mitomycin C (0.2 mg/mL
for 1 minute). Independent evaluation of a retrospective
nonrandomized study. Klin Monbl Augenheilkd. 1995;206(5)
:300–302. German. https://doi.org/10.1055/s-2008-1035446
19. Singh J, O’Brien C, Chawla HB. Success rate and
complications of intraoperative 0.2 mg/mL mitomycin C in
trabeculectomy surgery. Eye (Lond) 1995;9(Pt 4):460–466.
http://dx.doi.org/10.1038/eye.1995.107
20. Akova YA, Koç F, Yalvaç I, Duman S. Scleromalacia following
trabeculectomy with intraoperative mitomycin C. Eur J
Ophthalmol. 1999;9(1):63–65. http://dx.doi.org/10.1177/
112067219900900110
21. Fourman S. Scleritis after glaucoma filtering surgery with
mitomycin C. Ophthalmology. 1995;102(10):1569–1571.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0
